Receipt of guideline‐concordant care among young adult women with breast cancer

Abstract

Background Little is known about the real‐world care of young adult (YA) females (aged 20‐39 years) with breast cancer. This study describes factors associated with the receipt of guideline‐concordant care (GCC) among YAs. Methods The authors identified 1259 YA women with invasive breast cancer diagnosed in 2013 in the National Cancer Institute's Patterns of Care study. Hospital records were re‐abstracted, and treatment was verified. Using the National Comprehensive Cancer Network's 2013 breast cancer guidelines, the authors assessed the receipt of GCC by cancer subtype among a subset of YAs (n = 952). Associations between sociodemographic and clinical factors and GCC receipt were examined. Results Most YAs were 35 to 39 years old (51.2%) and partnered (56.4%); half had hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) tumors. GCC was found for 81.7% of YAs. Relationships between sociodemographic and clinical factors and GCC receipt differed by subtype. Stage was the only significant predictor of GCC receipt for all subtypes (stage II vs III: odds ratio [OR] for HR+/HER2+, 0.20; 95% confidence interval [CI], 0.08‐0.50; OR for HR−/HER2+, 0.13; 95% CI, 0.07‐0.25; OR for HR−/HER2−, 3.86; 95% CI, 1.55‐9.62; OR for HR+/HER2−, 2.81; 95% CI, 1.63‐5.80). Conclusions GCC is high among YAs with breast cancer. The effects of sociodemographic factors and treatment facility size on GCC differ by subtype. Consistent with recommendations, tumor biology, not age, is associated with GCC for all subtypes. Future studies should assess the effect of GCC on survival among YAs.

Management and Outcome of Young Women (≤40 Years) with Breast Cancer in Switzerland

“…The finding of high compliance with guidelines-recommended treatment in Switzerland mimics the results of a recent study from the United States. The authors analyzed data from 952 YWBC diagnosed in 2013 in the National Cancer Institute’s Patterns of Care Study and found that 81.7% received guideline-concordant care [ 27 ]. This is promising as adherence to treatment guidelines is associated with improved BC outcomes [ 28 ] and shows that physicians are willing to follow evidence-based guidelines for this specific group of patients.…”

Leonurine: a comprehensive review of pharmacokinetics, pharmacodynamics, and toxicology

“…Breast cancer and cervical cancer are the third- and fourth-largest malignant diseases that seriously threaten women’s health. Breast cancer and cervical cancer are prone to recurrence and metastasis and seriously affect the physical and mental health of patients ( Buskwofie et al, 2020 ; White et al, 2021 ). The results of the CCK8 assay, colony formation assay, and colony formation assay showed that LEO significantly inhibited MDA-MB-231 or SK-BR-3 cell proliferation at 400–800 μM concentrations.…”